News | October 31, 2025
NATCO launches Everolimus tablets, 1 mg
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The event will be attended by 35,000+ industry professionals
Subscribe To Our Newsletter & Stay Updated
